Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group (Q43289851)
Jump to navigation
Jump to search
scientific article published on 19 August 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group |
scientific article published on 19 August 2009 |
Statements
1 reference
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group (English)
1 reference
1 reference
Norikazu Masuda
1 reference
Yasuhiro Fujiwara
1 reference
Masashi Ando
1 reference
Kazuhiko Nakagami
1 reference
Mitsuhiro Mizutani
1 reference
Yasuo Hozumi
1 reference
Fumine Tsukamoto
1 reference
Mitsue Saito
1 reference
Shigeto Miura
1 reference
Kenji Eguchi
1 reference
Tetsu Shinkai
1 reference
Toru Watanabe
1 reference
Noriyuki Masuda
1 reference
Yasuo Ohashi
1 reference
Muneaki Sano
1 reference
Shinzaburo Noguchi
1 reference
19 August 2009
1 reference
1 reference
Identifiers
1 reference